Pharmidex Drug Metabolism Services
March 4, 2026
🔬 Unlock deeper insights into how your compound is processed in the body with
Pharmidex’s Drug Metabolism Services.
At
Pharmidex, we provide specialist drug metabolism studies using advanced UHPLC-high resolution/accurate mass spectrometry to support biotransformation understanding, cross-species metabolite profiling and structural characterisation of metabolites.
Our expert team can help you address challenges such as high clearance, identification of metabolically labile sites and potential reactive metabolism liabilities, helping you make data-driven decisions early in the discovery and development process.
Learn how our tailored approach can strengthen your metabolic profiling and accelerate your drug development programmes:
🔗
https://www.pharmidex.com/Drug-Metabolism-Service

#DrugMetabolism #MetaboliteProfiling #DMPK #UHPLC #MassSpectrometry #Preclinical#DrugDiscovery #Pharmidex

Pharmidex is pleased to announce that Martin Barrett , Head of Business Development, will be attending FROM DISCOVERY TO DISTRIBUTION – Making Pharmaceuticals 2026 on 21–22 April 2026 at the Coventry Building Society Arena, UK. Martin looks forward to meeting pharma innovators, formulation scientists, manufacturing leaders and strategic partners to discuss drug discovery, development, translational science, and end-to-end pharmaceutical solutions. If you’re attending, feel free to stop by for a chat and explore how Pharmidex can support your programmes from discovery through development.

Pharmidex will be attending Swiss Biotech Day 2026 on 4–5 May 2026 at the Congress Center Basel, Switzerland. We look forward to meeting founders, investors, biotech leaders and scientific partners to discuss drug discovery, translational development and strategic R&D opportunities. Feel free to catch us for a chat!

Pharmidex partners with Data Sciences International (DSI) to utilise industry-leading whole body plethysmography (WBP) systems, incorporating the patented Halcyon® pneumotach noise suppression technology. This enables the delivery of high-quality preclinical respiratory studies with enhanced clarity, sensitivity and confidence. By leveraging the robustness of DSI’s WBP platform alongside Pharmidex’s scientific expertise, we offer well-characterised models to assess: • Cough responses • Hypercapnic challenge responses • Functional respiratory changes across disease states such as asthma This integrated approach supports reliable and translatable assessment of airway function, disease progression and therapeutic efficacy, helping to de-risk programmes and drive better decision-making in preclinical development. Always keen to hear how others are advancing respiratory endpoints in their studies.




